HC Wainwright Issues Positive Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its price target boosted by equities researchers at HC Wainwright from $32.00 to $37.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 242.59% from the company’s previous close.

Other analysts have also issued reports about the stock. UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $10.80 on Thursday. Kura Oncology has a 52-week low of $9.06 and a 52-week high of $24.17. The stock has a market capitalization of $839.85 million, a price-to-earnings ratio of -4.66 and a beta of 0.86. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $18.08 and its 200 day simple moving average is $19.76.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Kura Oncology during the 1st quarter valued at $110,000. ProShare Advisors LLC raised its position in shares of Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after buying an additional 28,212 shares during the period. Avoro Capital Advisors LLC grew its stake in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after buying an additional 870,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Kura Oncology by 17.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after acquiring an additional 2,940 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.